Pleural solitary fibrous tumours (pSFTs) are uncommon soft tissue tumours of the pleura. that may recur and contribute to the patients’ demise. We analyzed a group of benign and malignant pSFTs for copy number alterations and for common mutations in oncogenes and tumour-suppressor genes. Malignant SFTs demonstrated more copy number alterations, especially 8q (c-myc) gain, 10q (include PTEN) loss, and 13q (Rb1) loss. Mutations were rare in this limited study.

Pleural solitary fibrous tumours (pSFTs) are uncommon soft tissue tumours of the pleura. that may recur and contribute to the patients’ demise. We analyzed a group of benign and malignant pSFTs for copy number alterations and for common mutations in oncogenes and tumour-suppressor genes. Malignant SFTs demonstrated more copy number alterations, especially 8q (c-myc) gain, 10q (include PTEN) loss, and 13q (Rb1) loss. Mutations were rare in this limited study.

Chan, Ho Ching. / Thesis M.Phil. Chinese University of Hong Kong 2016. / Includes bibliographical references (leaves 159-166). / Abstracts also in Chinese. / Title from PDF title page (viewed on 15, September, 2016).

Copy number variations (CNVs) are a major source of inter-individual genetic difference, accounting for a greater proportion of the human genome than other forms of variation. Recently, the identification of benign and pathogenic CNVs has improved due to arrays with increased coverage. Nevertheless, most CNVs have not been studied with great precision and questions persist regarding their exact breakpoint, gene content, frequency and functional impact. This is especially true in cancer, in which a role for CNVs as risk factors is under-explored. Li-Fraumeni syndrome (LFS) is a dominantly inherited disorder with an increased risk of early-onset breast cancer, sarcomas, brain tumors and other neoplasms in individuals harboring germline TP53 mutations. Known genetic determinants of LFS do not fully explain its clinical phenotype. In this thesis we describe the association between CNVs and LFS. First, by examining DNA from a healthy population and an LFS cohort using oligonucleotide arrays, we show that the number of CNVs per genome is well conserved in the healthy population, but remarkably enriched in these cancer-prone individuals. We found a significant increase in CNVs among carriers of germline TP53 mutations with a familial cancer history. Second, we find that ii specific CNVs at 17p13.1 are associated with LFS or developmental delay, depending on the exact breakpoint with respect to TP53. Using a purpose built array with 93.75% accuracy, we fine-mapped these microdeletions and find that they arise by Alu-mediated non-allelic homologous recombination, and contain common genes, whose under-expression distinguishes the two phenotypes. Third, we explore somatic CNVs in choroid plexus carcinoma tumor genomes. We show that this tumor is over-represented in LFS, and the number of somatic CNVs is associated with TP53 mutations and disease progression. These studies represent the first genomic analyses of LFS, and suggest a more generalized association between CNVs and cancer.

Copy number variations (CNVs) are a major source of inter-individual genetic difference, accounting for a greater proportion of the human genome than other forms of variation. Recently, the identification of benign and pathogenic CNVs has improved due to arrays with increased coverage. Nevertheless, most CNVs have not been studied with great precision and questions persist regarding their exact breakpoint, gene content, frequency and functional impact. This is especially true in cancer, in which a role for CNVs as risk factors is under-explored. Li-Fraumeni syndrome (LFS) is a dominantly inherited disorder with an increased risk of early-onset breast cancer, sarcomas, brain tumors and other neoplasms in individuals harboring germline TP53 mutations. Known genetic determinants of LFS do not fully explain its clinical phenotype. In this thesis we describe the association between CNVs and LFS. First, by examining DNA from a healthy population and an LFS cohort using oligonucleotide arrays, we show that the number of CNVs per genome is well conserved in the healthy population, but remarkably enriched in these cancer-prone individuals. We found a significant increase in CNVs among carriers of germline TP53 mutations with a familial cancer history. Second, we find that ii specific CNVs at 17p13.1 are associated with LFS or developmental delay, depending on the exact breakpoint with respect to TP53. Using a purpose built array with 93.75% accuracy, we fine-mapped these microdeletions and find that they arise by Alu-mediated non-allelic homologous recombination, and contain common genes, whose under-expression distinguishes the two phenotypes. Third, we explore somatic CNVs in choroid plexus carcinoma tumor genomes. We show that this tumor is over-represented in LFS, and the number of somatic CNVs is associated with TP53 mutations and disease progression. These studies represent the first genomic analyses of LFS, and suggest a more generalized association between CNVs and cancer.

Im Rahmen dieser Arbeit wurde Organisation, Expression und Funktion des humanen Peroxisomal-Testis-Spezifisch-1(PXT1)-Gens untersucht. Die mRNA des humanen PXT1-Gens enthält nicht wie bisher bekannt zwei Exons, sondern fünf Exons. Die Expression von drei putativen Exons stromaufwärts konnte in dieser Arbeit bestätigt werden. Die Ergebnisse qualitativer und quantitativer Real Time-PCR zeigen, dass sich das Exon 1 aus drei unterschiedlich gespleißten Einheiten (Exons 1a, 1b und 1c) zusammensetzt. Das humane PXT1-Gen unterliegt dem alternativen Spleißen, wovon die Exons 1b, 1c, 2 und 4 betroffen sind, was Sequenzanalysen zeigen. Sechs Transkripte konnten insgesamt identifiziert werden. Die zusätzlichen Exons haben Auswirkungen auf die Proteinstruktur aufgrund der Verlängerung des ORF, kodierend für einst 51 Aminosäuren, auf 134. Im längeren Protein wird die BH3 interacting domain (BID) nachgewiesen, von der eine proapoptotische Funktion bekannt ist. Aufgrund des alternativ gespleißten Exon 4 und der daraus resultierenden Leserasterverschiebung existiert ein verkürztes Protein, in dessen mRNA sich ein vorzeitiges Stopkodon befindet. Die proapoptotische Domäne ist nicht mehr nachweisbar. In silico-Analysen zeigen, dass die Sequenzen der Exons 1a und 1b von PXT1 sich mit dem KCTD20-Gen überlappen, das für einen Kaliumkanal kodiert.  Im Unterschied zum murinen, testisspezifischen Pxt1-Gen, ist das humane Homolog trotz Prädominanz im Testis auch schwächer in anderen Geweben nachweisbar.  Zur weiteren Klärung der proapoptotischen Funktion von Pxt1 in Keimzellen wurde am Mausmodell (Pxt1-Knockout-Maus) die Anzahl an DNA-Strangbrüchen untersucht. Im Vergleich zu den Kontrolltieren (C57BL/6J) zeigt die Pxt1-Knockout-Maus eine signifikant erhöhte Anzahl an Spermien mit DNA-Strangbrüchen. Dieses Ergebnis bestätigt die Annahme, dass das PXT1/Pxt1-Gen eine Art Entsorgungsfunktion für beschädigte Spermien ausübt. Im zeitlichen Verlauf zeigte sich aber, dass die Spermien der Knockout-Tiere nicht sensibler als die Wildtyp-Tiere auf DNaseI reagieren.  Als mögliches Kandidatengen für Mutationsanalysen bei Männern mit Fertilitätsstörungen wurden 55 Patienten mit Fertilitätsstörungen (Azoo- oder Oligozoospermie) auf Punktmutationen im PXT1 untersucht. Eine Mutation konnte nicht identifiziert werden. Des Weiteren wurde die DNA der Patienten auf Copy Number Variations analysiert. Sowohl heterozygote als auch homozygote Duplikationen konnten im Exon1, bestätigt mithilfe der arraybasierten Comparativen Genomischen Hybridisierung (aCGH), vereinzelt auch in Exon2 und Exon3 nachgewiesen werden. Zusätzlich konnte bei einem Patienten eine Deletion nachgewiesen werden. Die bestätigte Duplikation im Exon 1 besitzt aber keinen Krankheitswert, da sie in einem Kontrollkollektiv eine Prävalenz von 41% in heterozygoter und 10% in homozygoter Form besitzt.

Indiana University-Purdue University Indianapolis (IUPUI) / Cytochrome P450 2D6 (CYP2D6) is an important drug metabolizing enzyme that is involved in the metabolism of 20-25% of commonly prescribed drugs. There is interindividual variability in CYP2D6 enzyme activity and this leads to compromised metabolism of many drugs. Genetic and environmental factors explain only a part of the interindividual variability; the other factors that contribute to this variability are largely unknown. Hence, it becomes important to study CYP2D6 to understand the endogenous and exogenous factors that control its activity. The specific objective of this research was to determine the contribution of genetic and epigenetic factors in the regulation of CYP2D6 expression and activity. The specific aims were: (1) to identify the common CYP2D6 polymorphisms in Vietnamese and Filipino women with breast cancer and evaluate its association with plasma concentrations of endoxifen (an active metabolite of the breast cancer therapeutic drug, tamoxifen); (2) to identify the CYP2D6 copy number variations (CNVs) in these women and evaluate their association with endoxifen concentration; and (3) to identify microRNAs (miRNAs) that regulate the expression of CYP2D6 directly or indirectly. The results of this study indicated that: (1) in Vietnamese and Filipino women, the reduced function allele CYP2D6*10 was frequent (~55%) and it was significantly associated with reduced endoxifen concentration; (2) in these women, only 39% carried two copies of the CYP2D6 gene, the rest had a genomic imbalance for CYP2D6, primarily involving the CYP2D6(*36)n-*10 allele. However, carrying multiple copies of CYP2D6*36 allele did not significantly affect CYP2D6 activity, suggesting that multiple copies of a gene does not always translate to additive effects; and (3) microRNAs were identified to target HNF4A, a transcriptional factor that regulates CYP2D6 expression. These miRNAs are likely to play an important role in the indirect regulation of CYP2D6. Taken together, these results emphasize on the role of polymorphisms, CNVs and possibly miRNAs in the regulation of CYP2D6. These clinically important biomarkers will help to improve the efficacy and reduce the side effects of many CYP2D6 substrate drugs and thus contribute to personalization of drug therapy.

No description available.

O transtorno do espectro autista (ASD) é uma doença clinica e geneticamente heterogênea, com mecanismo etiológico ainda pouco conhecido. Assim, os principais objetivos deste trabalho foram descrever as características clínicas e genéticas de pacientes brasileiros com ASD, bem como determinar o risco de recorrência e a herdabilidade. Verificamos que a maioria das comorbidades avaliadas tem prevalência similar àquelas anteriormente descritas. A hipotonia exibiu maior prevalência no sexo feminino. A ausência de fala apresentou prevalência significativamente maior no grupo de pacientes com comorbidades, sendo que a gravidade da fala foi positivamente correlacionada com a presença das crises convulsivas. A herdabilidade estimada foi de 76% e o risco de recorrência ~5%. As alterações citogenéticas e os casos positivos para a Síndrome do X-Frágil explicaram cerca de 8% dos casos de ASD da nossa amostra. As CNVs nas regiões estudadas foram detectadas em 2,7% da amostra. Nós verificamos que há penetrância incompleta do ASD para as regiões. O estudo mais detalhado dos dois casos de duplicação da região 15q13.3, envolvendo somente o gene CHRNA7, mostrou que um dos pacientes (F5240) exibiu uma segunda CNV, possivelmente patogênica. A análise in silico sugeriu que genes que interagem diretamente com o CHRNA7 podem conter mutações patogênicas e, juntamente com a duplicação do 15q13.3, possivelmente estão envolvidos na etiologia do ASD. Este estudo mostrou que é necessário fazer uma ampla caracterização genética dos pacientes, para possibilitar o estudo dos possíveis mecanismos moleculares envolvidos na causa do ASD / Autism Spectrum Disorder (ASD) is a clinically and genetically heterogeneous disease and its etiological mechanisms are still poorly understood. The main objectives of this study were to describe the clinical and genetic features of Brazilian patients with ASD, and to determine the recurrence risk and heritability. Great part of the comorbidities assessed here had comparable prevalence to those of previous works. The hypotonia was significantly prevalent in the female sex. Absent speech was significantly more frequent in patients with comorbidities, and severity of speech problems was positively correlated with presence of seizures. Heritability was estimated as 76% and the recurrence risk as approximately 5%. Cytogenetic alterations and positive results for Fragile X Syndrome explain about 8% of the ASD etiology of our sample. The CNVs at the chromosomal regions 15q11-q13, 16p11.2 and 22q13 were present in 2.7% of the sample. Incomplete penetrance of ASD was observed for the 16p and 15q regions. Further investigation of the two cases with duplication of the region 15q13.3, involving only the CHRNA7 gene, revealed that one of them (F5240) exhibited a second possible pathogenic CNV. In silico analysis suggested that genes interacting directly with the CHRNA7 could harbor pathogenic mutations and, together with the duplication at 15q13.3, could be involved in the ASD etiology. This study showed the necessity of a broad genetic characterization of patients with ASD, to enable the elucidation of possible molecular mechanisms related to ASD etiology

Os transtornos do espectro autista (TEA) são condições neuropsiquiátricas caracterizadas por padrões comportamentais estereotipados, ausência ou limitação de comunicação verbal e de interação social recíproca. Diversos estudos têm mostrado que esses transtornos possuem etiologia genética complexa e heterogênea, o que dificulta a identificação dos fatores causais. Estima-se que cerca de 70% dos casos de TEA são idiopáticos. Portanto, com o objetivo de identificar mecanismos etiológicos associados aos TEA, utilizamos as seguintes estratégias: customização de uma lâmina de microarray CGH que possibilite a detecção não só de grandes CNVs, mas também de alterações menores do que 10 kbp, em exons e regiões UTR de genes potencialmente candidatos; a comparação entre os tipos de rearranjos detectados em pacientes sindrômicos e em não sindrômicos e, ainda, a investigação mais detalhada de uma família com indivíduos portadores de transtorno autista e síndrome de Asperger. Foram avaliados 103 portadores de TEA não sindrômicos e 18 sindrômicos, sendo as taxas de detecção de alterações potencialmente patogênicas, respectivamente, de 11,6% e 38,9%. Dentre as alterações detectadas 44,4% são menores do que 10 Kbp. Portanto, a estratégia de usar uma lâmina customizada, com alta densidade de sondas complementares aos exons e regiões não codificantes de genes potencialmente envolvidos na etiologia dos TEA, capaz de detectar tanto alterações grandes quanto pequenas, parece ser relevante na tentativa de elucidar o maior número de casos possíveis e melhor compreender esses transtornos. Além disso, essa lâmina também pode ser utilizada como uma ferramenta para auxiliar o diagnóstico clínico e o aconselhamento genético com um custo mais acessível em comparação a outras comerciais ou ao sequenciamento de última geração. Cerca de 33,3% das CNVs observadas afetam região UTR, sugerindo que mutações nessas regiões podem explicar uma proporção significativa dos casos nos quais não são detectadas alterações através de outros testes genômicos, visto que a maioria desses ainda não exploram adequadamente regiões não codificantes. Entre os pacientes autistas não sindrômicos verificou-se que a maioria dos genes afetados por CNVs estão envolvidos em duas principais funções biológicas - sinapses glutamatérgicas e orientação axonal, sugerindo que TEA não sindrômico pode ser causado por disfunção em genes diferentes envolvidos em processos fisiológicos comuns. Diferente do que observamos entre pacientes não sindrômicos, detectamos mais de uma alteração em um mesmo indivíduo ou alterações que englobam mais de um gene entre os pacientes sindrômicos, reforçando o modelo oligogênico para alguns casos de TEA. Por fim, os dados obtidos no estudo da família com portadores de síndrome de Asperger e transtorno autista sugere que a gravidade do quadro clínico possa estar relacionada ao número de mutações e possivelmente por duas mutações diferentes em ambos os alelos de um mesmo gene. Nossos resultados, além de apoiar o envolvimento dos genes MDGA2, FHIT, HTR2A, SHANK2, GRIA3, ZNF778, PRKCα, CDH15, DIAPH3, GCH1, GRM5, MARK1, SLC17A6, IMMP2L, BZRAP1, SYNGAP1, ANK3, MAP1A, GABRR2 e LAMC3 nos TEA também sugere novos genes candidatos: LRRC7, LRRIQ3, CADPS1, NUFIP, SEMA3A, SNAP29, MBD2, GAD2, DGKH e PARD3 / The autism spectrum disorders (ASD) are neuropsychiatric conditions typically characterized by social deficits, communication difficulties, stereotyped or repetitive behaviors and interests. Several studies have shown that these disorders have a complex and heterogeneous genetic etiology, which makes difficult to identify the causal factors. Approximately 70% of cases are idiopathic. In order to identify etiological mechanisms associated with ASD, we have used the following strategies: customized a microarray CGH platform that allows detection not only of large CNVs, but also alterations smaller than 10 kbp in exons and UTR regions of potential candidate genes, the comparison between the types of rearrangements detected in syndromic and non-syndromic patients and further, more detailed investigation of a family segregating both autistic disorder and Asperger syndrome. We evaluated 103 nonsyndromic and 18 syndromic patients by the custom-designed array and the detection rate of possibly pathogenic alterations were, respectively, 11.6% and 38.9%. Among these CNVs, 44.4% are smaller than 10 kbp. Therefore, the strategy of using a custom-designed array, enriched with probes targeted to genes potentially involved in the ASD etiology and able to detect both large and small CNVs, seems to be relevant in an attempt to elucidate the largest number of cases and to better understand these disorders. Furthermore, this platform can also be used as a tool to support the clinical diagnosis and genetic counseling with a more affordable cost compared to conventional other or next-generation sequencing. Approximately 33.3% of the observed CNVs affect UTR region, suggesting that mutations in non-coding regions might explain a significant proportion of ASD cases negative for most genomic screenings, which still do not explore adequately these regions. Among nonsyndromic autistic patients we found that most of the genes affected by CNVs are involved in two main biological functions - glutamatergic synapses and axonal guidance, suggesting that nonsyndromic ASD can be caused by dysfunction in different genes of a few common physiological processes. In contrast to our findings in nonsyndromic patients, we detected more than one alteration in a single individual or alterations that involve more than one gene among the syndromic patients, reinforcing the oligogenic model for some cases of ASD. Finally, the data obtained in the study of the family segregating both Asperger syndrome and autistic disorder suggests that the severity of ASD seems to be modulated by the number of hits and possibly by hits in both alleles of the same gene. Our results support the involvement of genes MDGA2, FHIT, HTR2A, SHANK2, GRIA3, ZNF778, PRKCα, CDH15, DIAPH3, GCH1, GRM5, MARK1, SLC17A6, IMMP2L, BZRAP1, SYNGAP1, ANK3, MAP1A, GABRR2 and LAMC3 in ASD etiology and also suggests new candidates: LRRC7, LRRIQ3, CADPS1, NUFIP, SEMA3A, SNAP29, MBD2, GAD2, DGKH and PARD3